Anti-epileptic Drugs Market By Drug Class (Hydantoin derivatives, Iminostilbenes, Long acting barbiturates, Succinimides, Benzodiazepines, Carbonic anhydrase inhibitors (CAI), GAMA- vinyl – GABA, Amino acid derivatives, Monosaccharide derivatives, Others : Valproic acid derivatives, Deoxy barbiturate, Phenyltriazine, Nicotinic acid derivatives, Sulphonamide derivatives) - Growth, Future Prospects & Competitive Analysis, 2017 – 2025

Epilepsy is a neurological disorder in which patient experiences epileptic seizures. These epileptic seizures are a result of the disturbance in the electrical communication in neurons. Seizures can vary from short period to long episodes of vigorous shaking. Epilepsy can be diagnosed in a patient only after one or more seizure episodes. Patients may have more than one type of seizure and these seizures usually follow the same pattern each time they occur to the patient. Causes of epilepsy include patient’s genetics, tumor or brain injuries. Epileptic seizures are of two types, i.e. focal and generalized depending on the affected area of the brain. Symptoms which occur before seizures include nausea, headache, strange feeling and visual loss. Anti-epileptic drugs are used to treat this neurological disorder.

This market analysis report on anti-epileptic drugs market provides a detailed analysis of the market. This report explains key market trends and aids industry leaders in their strategic initiative and decision making. The report provides market value and forecast for the anti-epileptic drugs market.

The scope of the report comprises demarcation of the market in terms of drug class and geographical distribution. The drug class segments are further categorized into hydantoin derivatives, iminostilbenes, long-acting barbiturates, succinimides, benzodiazepines, carbonic anhydrase inhibitors (CAI), GAMA- vinyl – GABA, amino acid derivatives, monosaccharide derivatives, and others. Others include valproic acid derivatives, deoxy barbiturate, phenyltriazine, nicotinic acid derivatives and sulphonamide derivatives. Each segment is analyzed considering market drivers and restraints for the market value of anti-epileptic drugs market. CAGRs are provided for the forecast year 2017-2025 for each segment.

Based on geographical demarcation, the report provides analysis of following geographical segments along with major countries:

  • North America
    • Canada
    • United States
  • Europe
    • Germany
    • United Kingdom
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Rest of Middle East and Africa

Market estimation is also elucidated for above-mentioned segments in anti-epileptic drugs market. This regional market estimation is proved granularly by segmenting the regions by drug class and countries. CAGRs are calculated for the forecast year 2017-2025.

This report provides key insights about the global anti-epileptic drugs market including market drivers & restraints, key trends, opportunities, and regional outlook. Analysis tools such as Porter’s five forces along with competitive landscape analysis are also incorporated in this report. Leading players in the global anti-epileptic market are also profiled in this report. The major players in the global anti-epileptic drugs market are Abide Therapeutics, Advicenne Pharma SA, Alexza Pharmaceuticals, Argentum Pharmaceuticals, GlaxoSmithKline (GSK) plc, GW Pharmaceuticals, Janssen Pharmaceuticals, Marinus Pharmaceuticals, Novartis Pharmaceuticals Corp, Otsuka Pharmaceuticals, Pfizer, Inc., Takeda Pharmaceutical Company Ltd and UCB Pharma.

Choose License Type
Published Date:  Dec 2017
Category:  Pharmaceuticals
Report ID:   58885
Report Format:   PDF
Pages:   120
Rating:    4.2 (50)
Connect With Us
+1-408-641-3282
24/7 Research Support